Robert A. Figlin, MD
Articles
Lenvatinib/Everolimus Shows Potential as Second-Line Therapy After CheckMate 9ER Regimen in RCC
May 29th 2021The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.
Selecting I-O Agents and Combinations for Patients With RCC
November 27th 2018Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.
Immunotherapy/TKI Combinations in Advanced RCC
November 8th 2018Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.
